Oncotarget最新文献_第4页

Integrated stress response (ISR) activation and apoptosis through HRI kinase by PG3 and other p53 pathway-restoring cancer therapeutics. PG3和其他可恢复p53通路的癌症治疗药物通过HRI激酶激活综合应激反应（ISR）和细胞凋亡。

Oncotarget Pub Date : 2024-09-17 DOI: 10.18632/oncotarget.28637

Xiaobing Tian, Wafik S El-Deiry

{"title":"Integrated stress response (ISR) activation and apoptosis through HRI kinase by PG3 and other p53 pathway-restoring cancer therapeutics.","authors":"Xiaobing Tian, Wafik S El-Deiry","doi":"10.18632/oncotarget.28637","DOIUrl":"10.18632/oncotarget.28637","url":null,"abstract":"Restoration of the p53 pathway has been a long-term goal in the field of cancer research to treat tumors with mutated p53 and aggressive clinical behavior. p53 pathway restoration in p53-deficient cancers can be achieved by small molecules via p53-dependent or p53-independent processes. Hereafter p53-independent restoration of p53-pathway-signaling in p53-deficient/mutated tumors is referred to as 'restoration of the p53 pathway'. We compare activation of p53 target genes by novel compounds PG3 and PG3-Oc, that activate p53-target genes in a p53-independent manner, and four mutant p53-activating compounds while Nutlin-3a is used as negative control. PG3 and PG3-Oc upregulate p21, PUMA, and DR5 in five cancer cell lines with various p53 mutational statuses through ATF4 (Activating Transcriptional Factor 4) and integrated stress response (ISR) independent of p53. Mutant p53-targeting compounds induce expression of the 3 major downstream p53 target genes and ATF4 in a highly variable and cell-type-dependent manner. PG3 treatment activates ATF4 through ISR via kinase HRI (Heme-Regulated Inhibitor). ATF4 mediates upregulation of PUMA, p21, and NAG-1/GDF15 (Nonsteroidal anti-inflammatory drug-activated gene 1). We note that PUMA mediates apoptosis through activation of caspase-8 in HT29 cells and potentially caspase-10 in SW480 cells. We provide a novel mechanism engaged by PG3 to induce cell death via the HRI/ATF4/PUMA axis. Our results provide unique insights into the mechanism of action of PG3 as a novel cancer therapeutic targeting p53 pathway-like tumor suppression.","PeriodicalId":19499,"journal":{"name":"Oncotarget","volume":"15 ","pages":"614-633"},"PeriodicalIF":0.0,"publicationDate":"2024-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11407758/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142292675","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Retraction: Myeloid ecotropic viral integration site 1 inhibits cell proliferation, invasion or migration in human gastric cancer. 撤回：髓样生态病毒整合位点 1 可抑制人胃癌的细胞增殖、侵袭或迁移

Oncotarget Pub Date : 2024-09-17 DOI: 10.18632/oncotarget.28649

Fei Song, Hong Wang, Yingying Wang

引用次数: 0

The emerging role of AI in enhancing intratumoral immunotherapy care. 人工智能在加强肿瘤内免疫疗法护理方面的新兴作用。

Oncotarget Pub Date : 2024-09-17 DOI: 10.18632/oncotarget.28643

Abin Sajan, Abdallah Lamane, Asad Baig, Korentin Le Floch, Laurent Dercle

{"title":"The emerging role of AI in enhancing intratumoral immunotherapy care.","authors":"Abin Sajan, Abdallah Lamane, Asad Baig, Korentin Le Floch, Laurent Dercle","doi":"10.18632/oncotarget.28643","DOIUrl":"https://doi.org/10.18632/oncotarget.28643","url":null,"abstract":"The emergence of immunotherapy (IO), and more recently intratumoral IO presents a novel approach to cancer treatment which can enhance immune responses while allowing combination therapy and reducing systemic adverse events. These techniques are intended to change the therapeutic paradigm of oncology care, and means that traditional assessment methods are inadequate, underlining the importance of adopting innovative approaches. Artificial intelligence (AI) with machine learning algorithms and radiomics are promising approaches, offering new insights into patient care by analyzing complex imaging data to identify biomarkers to refine diagnosis, guide interventions, predict treatment responses, and adapt therapeutic strategies. In this editorial, we explore how integrating these technologies could revolutionize personalized oncology. We discuss their potential to enhance the survival and quality of life of patients treated with intratumoral IO by improving treatment effectiveness and minimizing side effects, potentially reshaping practice guidelines. We also identify areas for future research and review clinical trials to confirm the efficacy of these promising approaches.","PeriodicalId":19499,"journal":{"name":"Oncotarget","volume":"15 ","pages":"635-637"},"PeriodicalIF":0.0,"publicationDate":"2024-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11407757/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142292677","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Trained and ready - the case for an inflammatory memory for hematopoietic stem and progenitor cells in the AML niche. 训练有素、蓄势待发--急性髓细胞性白血病龛位中造血干细胞和祖细胞的炎症记忆案例。

Oncotarget Pub Date : 2024-09-04 DOI: 10.18632/oncotarget.28642

Ding-Wen Chen, Eric K Wafula, Peter Kurre

{"title":"Trained and ready - the case for an inflammatory memory for hematopoietic stem and progenitor cells in the AML niche.","authors":"Ding-Wen Chen, Eric K Wafula, Peter Kurre","doi":"10.18632/oncotarget.28642","DOIUrl":"10.18632/oncotarget.28642","url":null,"abstract":"Lifelong hematopoiesis is sustained by crosstalk between hematopoietic stem and progenitor cells (HSPCs) and specialized bone marrow niches. Acute myeloid leukemia (AML) upends that balance, as leukemic blasts secrete factors that remodel the bone marrow into a self-reinforcing leukemic niche. The inflammatory secretome behind this compartmental adaptation accounts for a progressive decline in hematopoietic function that leads to diagnosis and persists through early treatment. Not surprisingly, the mediators of an acute inflammatory injury and HSPC suppression have attracted much attention in an effort to alleviate morbidity and improve outcomes. HSPCs typically recover during disease remission and re-expand in the bone marrow (BM), but little is known about potentially lasting consequences for stem cells and progenitors. We recently showed that AML-experienced HSPCs actively participate in the inflammatory process during leukemic progression. HSPCs are constituent components of the innate immune system, and elegant studies of infection and experimental inflammation over the past decade have described the generation of an adoptively transferable, innate immune memory. Building on this paradigm, we discuss the potential translational relevance of a durable legacy in AML-experienced HSPC.","PeriodicalId":19499,"journal":{"name":"Oncotarget","volume":"15 ","pages":"609-613"},"PeriodicalIF":0.0,"publicationDate":"2024-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11376595/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142140695","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Generative AI in oncological imaging: Revolutionizing cancer detection and diagnosis. 肿瘤成像中的生成式人工智能：革命性的癌症检测和诊断。

Oncotarget Pub Date : 2024-09-04 DOI: 10.18632/oncotarget.28640

Yashbir Singh, Quincy A Hathaway, Bradley J Erickson

引用次数: 0

Artificial intelligence: A transformative tool in precision oncology. 人工智能：精准肿瘤学的变革性工具。

Oncotarget Pub Date : 2024-08-26 DOI: 10.18632/oncotarget.28639

Jeremy McGale, Matthew J Liao, Egesta Lopci, Aurélien Marabelle, Laurent Dercle

引用次数: 0

Inhibition of miR-10b treats metastatic breast cancer by targeting stem cell-like properties. 抑制 miR-10b 可通过靶向干细胞样特性治疗转移性乳腺癌。

Oncotarget Pub Date : 2024-08-26 DOI: 10.18632/oncotarget.28641

Alan Halim, Nasreen Al-Qadi, Elizabeth Kenyon, Kayla N Conner, Sujan Kumar Mondal, Zdravka Medarova, Anna Moore

{"title":"Inhibition of miR-10b treats metastatic breast cancer by targeting stem cell-like properties.","authors":"Alan Halim, Nasreen Al-Qadi, Elizabeth Kenyon, Kayla N Conner, Sujan Kumar Mondal, Zdravka Medarova, Anna Moore","doi":"10.18632/oncotarget.28641","DOIUrl":"10.18632/oncotarget.28641","url":null,"abstract":"Despite advances in breast cancer screening and treatment, prognosis for metastatic disease remains dismal at 30% five-year survival. This is due, in large, to the failure of current therapeutics to target properties unique to metastatic cells. One of the drivers of metastasis is miR-10b, a small noncoding RNA implicated in cancer cell invasion, migration, viability, and proliferation. We have developed a nanodrug, termed MN-anti-miR10b, that delivers anti-miR-10b antisense oligomers to cancer cells. In mouse models of metastatic triple-negative breast cancer, MN-anti-miR10b has been shown to prevent onset of metastasis and eliminate existing metastases in combination with chemotherapy, even after treatment has been stopped. Recent studies have implicated miR-10b in conferring stem cell-like properties onto cancer cells, such as chemoresistance. In this study, we show transcriptional evidence that inhibition of miR-10b with MN-anti-miR10b activates developmental processes in cancer cells and that stem-like cancer cells have increased miR-10b expression. We then demonstrate that treatment of breast cancer cells with MN-anti-miR10b reduces their stemness, confirming that these properties make metastatic cells susceptible to the nanodrug actions. Collectively, these findings indicate that inhibition of miR-10b functions to impair breast cancer cell stemness, positioning MN-anti-miR10b as an effective treatment option for stem-like breast cancer subtypes.","PeriodicalId":19499,"journal":{"name":"Oncotarget","volume":"15 ","pages":"591-606"},"PeriodicalIF":0.0,"publicationDate":"2024-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11348941/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142073490","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Retraction: MicroRNA-138 acts as a tumor suppressor in non small cell lung cancer via targeting YAP1. 撤回：MicroRNA-138 通过靶向 YAP1 在非小细胞肺癌中发挥肿瘤抑制作用

Oncotarget Pub Date : 2024-08-26 DOI: 10.18632/oncotarget.28645

Ling Xiao, Hui Zhou, Xiang-Ping Li, Juan Chen, Chao Fang, Chen-Xue Mao, Jia-Jia Cui, Wei Zhang, Hong-Hao Zhou, Ji-Ye Yin, Zhao-Qian Liu

引用次数: 0

A nanobody against the V-ATPase c subunit inhibits metastasis of 4T1-12B breast tumor cells to lung in mice. 针对 V-ATPase c 亚基的纳米抗体可抑制 4T1-12B 乳腺癌细胞向小鼠肺部转移。

Oncotarget Pub Date : 2024-08-14 DOI: 10.18632/oncotarget.28638

Zhen Li, Mohammed A Alshagawi, Rebecca A Oot, Mariam K Alamoudi, Kevin Su, Wenhui Li, Michael P Collins, Stephan Wilkens, Michael Forgac

引用次数: 0

Retraction: The crucial role of SRPK1 in IGF-1-induced EMT of human gastric cancer. 撤回：SRPK1在IGF-1诱导的人类胃癌EMT中的关键作用

Oncotarget Pub Date : 2024-08-14 DOI: 10.18632/oncotarget.28431

Hong Wang, Chunlei Wang, Wenling Tian, Yanfen Yao

引用次数: 0